Kornimate/medical-research-clean huggingface dataset:
oxygen saturation and perfusion index ın neonates at high altitude

Conditions: Critical Congenital Heart Disease; High Altitude

Summary: congenital heart diseases are among the most common congenital anomalies and occur with an incidence of approximately 8ınd12 / 1,000 live births worldwide. this figure does not cover minor lesions such as bicuspid aortic valves and small atrial or ventricular septal defects. most of these defects do not need treatment or treatment is needed after infancy. other defects are severe and usually require early treatment in the neonatal period. critical congenital heart disease is defined as structural heart defects that are associated with hypoxia in the neonatal period and have significant morbidity and mortality potential in early life. critical congenital heart disease is estimated to be \~3 in 1000 live births. it is estimated that 50% of congenital heart diseases are detected by prenatal ultrasound. even if a standard neonatal examination is performed, 13 to 55% of patients with critical congenital heart disease can be discharged from the hospital without being diagnosed. screening of infants with non-invasive oxygen saturation measurement has been proposed as an adjunct to early detection of critical congenital heart disease. the american academy of pediatrics, the american cardiology foundation and the american heart association have targeted 7 specific lesions for the pulse oximetry screening protocol: truncus arteriosus, transposition of the great arteries, tricuspid atresia, tetralogy of fallot, total pulmonary venous return anomaly, hypoplastic left heart syndrome and pulmonary atresia. the reference values of peripheral perfusion (ppi) index has been established for normal newborns between 1 and 120 h of age. lower ppi values than 0.70 may indicate illness. including cut-off values for ppi in pulse-oximetry screening for duct dependent congenital heart disease is a promising tool for improving the detection of critical congenital heart disease with duct-dependent systemic circulation. we aimed to investigate screening critical congenital heart disease and also to establish normal values of oxygen saturation and perfusion index at high altitude.


Eligibility criteria:
inclusion criteria: * the newborns delivered in ataturk university hospital and ≥34 weeks of gestational age were eligible for the study. exclusion criteria: * outborn and premature babies (\<34 weeks) were not included. babies with a prenatal diagnosis of congenital heart disease were excluded.
irreparable rotator cuff tears treatment. comparison of two methods: with and without biceps tendon augmentation

Conditions: Massive Rotator Cuff Tears; Rotator Cuff Injuries; Shoulder Pain Chronic

Summary: management of massive rotator cuff tears (mrct) is associated with high rates of failure. the long head of the biceps tendon augmentation (lhbta) by reinforcement of the reconstruction and additional blood supply may improve healing and provide better outcome than partial repair only.

patients with irreparable supraspinatus muscle (ssp) tear, and complete infraspinatus muscle (isp) tear are including in the prospective, comparative study. excluding criteria consist of: problems or previous surgery of contralateral shoulder, subscapularis muscle tear larger than stage 2 by lafosse classification, uncontrolled diabetes and previous surgery. first group consisting of patients treated by partial cuff repair with lhbta. second group is comparative group consisting of patients treated by only partial cuff repair without lhbta. group stratification depends on quality of the biceps tendon. in case of good tendon quality - its used for biological augmentation, if it's degenerated- tenotomy of the tendon and only partial repair is performing. irreparability is defined as ssp ≥ 3 in goutallier classification and stage 3 in patte classification what is preoperatively assessed by mri. assessment tools consisting of range of motion (rom), strength measurements in position adequate to assess reconstructing tendons and muscles force, acromio-humeral index (ahi), constant, sst, hamada, and sugaya scores. goutallier classification for ssp and isp and diameter of the teres minor muscle (tmn). radiological and clinical assessment is performing one year after the surgery

Eligibility criteria:
inclusion criteria: massive and irreparable rotator cuff tear: * chronic supraspinatus tear with retraction grade 3 and muscle fatty infiltration ( measured in mri ) \> 3\* * infraspinatus tear with retraction and fatty muscle degeneration exclusion criteria: * previosus surgery * imposibility to performed mri * diabetes * no compliance

Keywords: massive rotator cuff partial repair biceps augmentation shoulder arthroscopy
a plaque test comparing the anti-psoriatic effect of marketed products for topical use for psoriasis vulgaris

Conditions: Psoriasis Vulgaris

Summary: the purpose of the study is to compare the anti-psoriatic effect of marketed products with daivobet® ointment in a plaque test


Eligibility criteria:
inclusion criteria: (in summary) * subjects having understood and signed an informed consent form * all skin types * subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs or trunk. the lesions must have a total size suitable for application. the subjects should be asked if their lesions have been stable * subjects willing and able to follow all the study procedures and complete the whole study * subjects affiliated to social security system exclusion criteria: (in summary) * females who are pregnant, of child-bearing potential and who wish to become pregnant during the study, or who are breast feeding * subjects using biological therapies (marketed or not marketed) with a possible effect on psoriasis (e.g. alefacept, efalizumab, etanercept, infliximab, adalimumab) within 12 weeks prior to study drug administration * systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin d-analogues, retinoids, immunosuppressants) within the 4-week period prior to randomisation * subjects using one of the following topical drugs for the treatment of psoriasis within four (4) weeks prior to study drug administration: - potent or very potent (who group iii-iv) corticosteroids - puva or grenz ray therapy * subjects using one of the following topical drugs for the treatment of psoriasis within two (2) weeks prior to study drug administration: - who group i-ii corticosteroids - topical retinoids - vitamin d-analogues - topical immunomodulators (e.g. macrolides) - anthracen derivatives - tar - salicylic acid - uvb therapy * subjects with skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds within the plaque test areas
engineering immune organoids to study pediatric cancer

Conditions: Brain Tumor; Kidney Tumor; Neuroblastoma; Sarcoma

Summary: to engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (ipsc)


Eligibility criteria:
inclusion criteria: * age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied * medical suspicion or diagnosis of one of the following diseases, regardless of stage: * brain tumors * renal tumors * neuroblastoma * sarcomas * adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. patient should be able and willing to comply with study visits and procedures as per protocol. * affiliated to a social security system or beneficiary of the same. exclusion criteria: * any histology not mentioned in the inclusion criteria * adult patient or parents/guardians incapable/incapable of giving its/their consent * patients deprived of their liberty by a judicial or administrative decision
health and sleep assessment after the strasbourg attacks of december 11, 2018

Conditions: Stress Disorders, Post-Traumatic

Summary: evaluation of the prevalence of post-traumatic stress disorder (ptsd), associated risk factors, health care consumption, and sleep disorders in a civilian population exposed to the december 11, 2018, attacks in strasbourg. terrorist attacks have unfortunately become all too frequent on our territory in recent years. a better knowledge of the psychological and psychiatric repercussions on exposed populations is essential in order to better prevent and treat disorders that can have a major functional impact on the lives of exposed individuals and to adapt care during future similar events


Eligibility criteria:
inclusion criteria: * major subject (≥ 18 years old), * having been exposed to the attacks of december 11, 2018 in strasbourg directly or indirectly (presence at the scene or close relative present at the scene) * subject who has not expressed his opposition, after information, to the reuse of his data for the purpose of this research exclusion criteria: * subject who has expressed opposition to participating in the study * subject under guardianship, curatorship or legal protection

Keywords: stress disorders disorders post-traumatic
evaluation of enzastaurin in the treatment of persistent or recurrent ovarian or primary peritoneal cancer

Conditions: Ovarian Cancer; Neoplasms; Carcinoma

Summary: the purpose is to assess the efficacy and toxicity of the study agent, enzastaurin, in participants with recurrent or persistent ovarian cancer.


Eligibility criteria:
inclusion criteria: * participants must have recurrent or persistent epithelial ovarian or primary peritoneal carcinoma. * all participants must have measurable disease. * participants must have at least one "target lesion" to be used to assess response on this protocol. * participants must not be eligible for a higher priority gog protocol, if one exists. * participants who have received one prior regimen must have a gog performance status of 0, 1, or 2. participants who have received two prior regimens must have a gog performance status of 0 or 1. * any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. continuation of hormone replacement therapy is permitted. * any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least four weeks prior to registration. * participants must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. * participants must not have received any non-cytotoxic therapy for management of recurrent or persistent disease. * participants of child-bearing potential must have a negative serum pregnancy test prior to study entry and be practicing an effective form of contraception (for example, intrauterine device \[iud\], birth control pills, or barrier device) during and for 3 months after discontinuation of study treatment. exclusion criteria: * participants with previous enzastaurin treatment. * participants who have received radiation to more than 25% of marrow-bearing areas * participants with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy. * participants who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. * participants who are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin (refer to concomitant medications for a discussion of enzyme inducing anti-epileptic drugs \[eiaeds\]). * participants who are receiving concurrent administration of any other systemic anticancer therapy except for a biphosphonate if patient has bony metastases. * participants who have received prior therapy with non-cytotoxic agents (i.e. bevacizumab). * participants with serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ecg) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study.

Keywords: recurrent cancer
ultrasound-guided cryobiopsy of mediastinal/hilar lymph nodes

Conditions: Lung Cancer (NSCLC)

Summary: ebus-guided cryobiopsy of mediastinal and hilar lymph nodes has shown to be a useful diagnostic tool to obtain tissue for histological analysis and further targeted therapies in lung malignancies. due to the large size and better quality of the tissue samples, a higher diagnostic yield than with transbronchial needle aspiration (tbna) can be expected, especially in non-solid tumors. in previous studies different biopsy protocols were used. the freezing time of cryoprobe (which defines the sample sizes) ranged from 3 to 7 s and the number of biopsies was between 1 and 4 samples. it is therefore unclear what freezing times and biopsy frequency are required to obtain the best histological information.

ebus-guided cryobiopsy of mediastinal and hilar lymph nodes has shown to be a useful diagnostic tool to obtain tissue for histological analysis and further targeted therapies in lung malignancies. due to the large size and better quality of the tissue samples, a higher diagnostic yield than with transbronchial needle aspiration (tbna) can be expected, especially in non-solid tumors. in previous studies different biopsy protocols were used. the freezing time of cryoprobe (which defines the sample sizes) ranged from 3 to 7 s and the number of biopsies was between 1 and 4 samples. it is therefore unclear what freezing times and biopsy frequency are required to obtain the best histological information. this study will analyze whether the freezing time influences the diagnostic yield in cb of mediastinal lymphadenopathies. additionally we will evaluate the influence of the number of biopsies on the diagnostic yield.

Eligibility criteria:
inclusion criteria: * at least one mediastinal lesion or hilar 1 cm or longer in the short axis requiring diagnostic bronchoscopy * age between 18 and 90 years * written informed consent after participant's information exclusion criteria: * age \ 90 years * lacking ability to form an informed consent (including impaired judgement, communication barriers) * contraindication against bronchoscopy (e.g. co-morbidities) * mediastinal abscess or cyst * extraordinary blood supply of the lesion visualized by ebus bronchoscope * inr \> 1.5 or thrombocytes \< 100 g/l * clopidogrel or other new antiplatelet drugs within 7 days before biopsy (salicylic acid alone allowed) * anticoagulation with noac within 48 hours before biopsy * pulmonary lesions suspicious of lung carcinoma

Keywords: ebus cryobiopsy tbna bronchoscopy
pelvic floor exercises in patients with sjögren's

Conditions: Sjögren; Sjögren Syndrome

Summary: when the literature is examined, the positive effects of pelvic floor exercises on sexual functions have been supported by studies. however, the effectiveness of pelvic floor exercises on pelvic floor problems in women with sjögren has not been examined in the literature. the aim of this study is in order to examine the effect of pelvic floor exercises on sexual function in women with primer sjögren syndrome (pss), since these negativities affect both the quality of life and sexual functions in women with pss. this is a randomized controlled trial examining the effect of 8 weeks of home-based pelvic floor exercises on pain, sexual dysfunction and quality of life on women with sjogren's.

demographic information form, haq, vas, pelvic pain impact questionnaire (ppiq), pelvic floor distress scale-20, female sexual function inventory (fsfi), pelvic floor impact questionnaire (pfiq-7) will be applied to female patients with sjögren's who meet the inclusion criteria.after the initial evaluation, patients will be randomized to intervention and control groups. the intervention group will be taught home exercises including fast and slow contraction and keeping the muscles around the pelvic floor in different positions (sitting, standing, lying) and will be asked to do them every day for 8 weeks according to the determined protocol. for eight weeks, the patients will be supported by the phone by the physiotherapist and at the same time, they will be checked whether they do the exercises. the control group will be given training on pelvic floor anatomy. at the end of eight weeks, patients will be given a final evaluation and the results will be analyzed.

Eligibility criteria:
inclusion criteria: * be woman * having a diagnosis of primary sjogren's * no comorbidities other than sjögren's syndrome * not having had pelvic floor surgery * being sexually active * voluntary and consent to participate in the study exclusion criteria: * other rheumatological diseases * urogynecological diseases * sarcoidosis * lymphoma * having had a non-cesarean gynecological operation * infection

Keywords: sjögren pelvic floor exercises
serum dickkopf-4 as a biomarker for the diagnosis and treatment of gastrointestinal stromal tumor

Conditions: Gastrointestinal Stromal Tumor

Summary: our study aims to evaluate the role of dickkopf-4 as biomarkers in the treatment of gastrointestinal stromal tumor.

to identify whether dickkopf-4 (dkk4) could be a potential biomarker for diagnosis and prognosis in patients with gastrointestinal stromal tumor (gist). serum was collected from 50 patients with gist. serological levels of dkk4 were examined by enzyme-linked immunosorbent assay (elisa). the sensitivity and specificity was compared with modified nih risk criteria. a 3-year follow-up was monitored to evaluate the correlation between dkk4 serum levels and relapse-free or overall survival. the expression of dkk4 in gist tumor tissues was also evaluated using immunohistochemistry staining.

Eligibility criteria:
inclusion criteria: * primary gastrointestinal stromal tumor confirmed pathologically by surgery or biopsy * age from 18 - 70 years * no serious organic and mental illness; exclusion criteria: * pregnancy * no pathologic result * suffering other malignancies at the same time.

Keywords: dkk4 gastrointestinal stromal tumor biomarker
ultrasound-guided erector spinae plane block versus retrolaminar block for postoperative analgesia in thoracotomy

Conditions: Postoperative Analgesia; Retrolaminar Block; Ultrasound-guided Erector Spinae Plane Block; Thoracotomy

Summary: comparing efficacy of ultrasound-guided erector spinae plane block versus retrolaminar block for postoperative analgesia in patients undergoing thoracotomy

thoracotomy is one of the most painful surgical procedures. the reported incidence of persistent pain after thoracic surgery (post thoracotomy pain syndrome) has been reported in 20%-70% of patients. inadequately treated post thoracotomy pain can have several negative consequences. therefore, pain relief is essential to facilitate coughing and deep breathing and to promote early mobilization. thoracic epidural analgesia and thoracic paravertebral block are strongly recommended techniques for managing post thoracotomy pain to reduce opioid use and the related adverse effects as hypoventilation, depression of cough reflex, nausea and vomiting. however, they can be technically challenging to perform and are associated with up to 15% failure rate in thoracic epidural analgesia and potential risk of pneumothorax in thoracic paravertebral block. erector spinae plane block is a relatively novel ultrasound-guided regional technique. its application in patients with chronic thoracic neuropathic pain and acute surgical pain has been described by forero et al. retrolaminar block is an easy and safe analgesic technique. it has been reported to be satisfactory for post-operative analgesia after breast surgery. to our knowledge there is no clinical studies, comparing the effectiveness of both blocks on postthoracotomy pain, has been reported.

Eligibility criteria:
inclusion criteria: * adult patients aged 21-65 years old of both sexes. * patients were scheduled for elective thoracotomy. * their asa physical status classification is ii-iii. exclusion criteria: * patients' refusal. * local infection at the site of block. * coagulation abnormalities. * sever spinal deformity e.g. scoliosis. * known hypersensitivity to local anesthetics. * mental dysfunction and cognitive disorders. * history of drug abuse and chronic analgesic use.
intensive versus conventional glycemic control in diabetic foot ulcer healing

Conditions: Diabetic Foot Ulcer

Summary: diabetic foot ulcer is one of the most serious, most costly and at times life threatening complication of diabetes. the lifetime incidence of foot ulcer occurrence in diabetes is up to 25%. despite the advent of numerous types of wound dressings and off-loading mechanisms, the ulcer healing rates in diabetes have remained dismally low. hyperglycemia impairs the inflammatory, proliferative and remodeling phases of an ulcer. there are retrospective studies linking improvement of hba1c to wound area healing rate. the investigators hypothesised that intensive glycemic control in a patient of diabetic foot ulcer improves the healing process. to explore this hypothesis, the investigators are conducting this randomized control trial with the primary aim of wound healing in patients of diabetic foot ulcer on either intensive glycemic treatment or conventional (pre-existing) glycemic treatment.


Eligibility criteria:
inclusion criteria: 1. age \>18 years 2. patients of dm according to ada guidelines 3. hba1c \>8% and/or fbg \>130 on 3 consecutive occasions 4. dfu: wagner grade 2 \& 3 or uts 2-3b 5. duration of ulcer \<12 weeks 6. wound size: \>1cm2 7. willingness to sign consent form \& participate in the study 8. capacity to attend visits at hospital for review exclusion criteria: 1. diagnosis with unpredictable healing ability e.g. malignancy, depression, hiv, ctd, steroid use 2. dialysis requiring ckd \& egfr \<30 ml/min 3. active charcot foot 4. pedis 4: life threatening dfu 5. pregnancy 6. abi \<= 0.7 7. refusal to give informed consent

Keywords: diabetic foot ulcer intensive glycemic control